QTNT - Quotient Limited

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
9.72
-0.31 (-3.09%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close10.03
Open10.04
Bid9.00 x 1000
Ask11.92 x 800
Day's Range9.64 - 10.35
52 Week Range3.69 - 10.35
Volume774,894
Avg. Volume382,198
Market Cap632.106M
Beta (3Y Monthly)1.30
PE Ratio (TTM)N/A
EPS (TTM)-1.98
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.33
Trade prices are not sourced from all markets
  • GlobeNewswire19 hours ago

    Quotient Limited to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

    JERSEY, Channel Islands, Feb. 15, 2019 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that today announced that the Company’s Chief.

  • Thomson Reuters StreetEvents11 days ago

    Edited Transcript of QTNT earnings conference call or presentation 31-Jan-19 1:30pm GMT

    Q3 2019 Quotient Ltd Earnings Call

  • Quotient Ltd (QTNT) Q3 2019 Earnings Conference Call Transcript
    Motley Fool15 days ago

    Quotient Ltd (QTNT) Q3 2019 Earnings Conference Call Transcript

    QTNT earnings call for the period ending December 31, 2018.

  • Quotient (QTNT) Reports Q3 Loss, Tops Revenue Estimates
    Zacks16 days ago

    Quotient (QTNT) Reports Q3 Loss, Tops Revenue Estimates

    Quotient (QTNT) delivered earnings and revenue surprises of -12.20% and 8.44%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press16 days ago

    Quotient: Fiscal 3Q Earnings Snapshot

    On a per-share basis, the Eysins, Jersey-based company said it had a loss of 46 cents. The blood test developer posted revenue of $6.7 million in the period. Quotient shares have risen 31 percent since ...

  • GlobeNewswire16 days ago

    Quotient Limited Provides an Update on Extended Immunohematology Microarray Performance and on the Commencement of the Initial Serological Disease Screening Field Trial together with Third Quarter Fiscal 2019 Results

    Development data provides positive results for extended IH microarray panelField trial for initial Serological Disease microarray panel has commenced Reagent revenue growth of.

  • Quotient (QTNT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks23 days ago

    Quotient (QTNT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Quotient (QTNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswirelast month

    Quotient Limited to Report Fiscal Third Quarter 2019 Financial Results and Host Conference Call

    JERSEY, Channel Islands, Jan. 17, 2019 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third.

  • Could Quotient Limited’s (NASDAQ:QTNT) Investor Composition Influence The Stock Price?
    Simply Wall St.2 months ago

    Could Quotient Limited’s (NASDAQ:QTNT) Investor Composition Influence The Stock Price?

    If you want to know who really controls Quotient Limited (NASDAQ:QTNT), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as shareholders, Read More...

  • Hedge Funds Are Betting On Quotient Limited (QTNT)
    Insider Monkey2 months ago

    Hedge Funds Are Betting On Quotient Limited (QTNT)

    Before we spend many hours researching a company, we’d like to analyze what insiders, hedge funds and billionaire investors think of the stock first. We would like to do so because the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out what the billionaire investors and hedge funds think of […]

  • TheStreet.com2 months ago

    Here's a Handful of Small Biotechs Where Insiders Are Buying

    The market has acted a bit better so far this week on some signs trade tensions between the United States and China might be lessening a hair. Quotient shares have had a decent year despite what has been a challenging year in this space but have pulled back from their highs this summer. Quotient's stock receives little analyst coverage in the States despite a market cap of around $400 million.

  • GlobeNewswire2 months ago

    Quotient Limited Announces Closing of Underwritten Offering of Ordinary Shares

    Quotient Limited (QTNT) (the Company), a commercial-stage diagnostics company, today announced the closing of its previously announced underwritten public offering of 10,615,385 ordinary shares at a price to the public of $6.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,384,615 additional ordinary shares. The net proceeds to the Company from this offering were approximately $64.6 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds of the offering primarily to fund the ongoing scale up and, if approved, commercialization of MosaiQ and for working capital and other general corporate purposes.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of QTNT earnings conference call or presentation 5-Nov-18 1:00pm GMT

    Q2 2019 Quotient Ltd Earnings Call

  • GlobeNewswire2 months ago

    Quotient Limited Announces Pricing of Underwritten Offering of Ordinary Shares

    Quotient Limited (QTNT) (the Company), a commercial-stage diagnostics company, today announced the pricing of its previously announced underwritten public offering of 9,230,770 ordinary shares at a price to the public of $6.50 per share. The net proceeds to the Company from this offering are expected to be approximately $56.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. All of the ordinary shares sold in the offering were offered by the Company.

  • GlobeNewswire2 months ago

    Quotient Limited Announces Proposed Underwritten Offering of Ordinary Shares

    Quotient Limited (QTNT) (the Company), a commercial-stage diagnostics company, today announced the Company intends to commence an underwritten public offering of its ordinary shares. All of the ordinary shares to be sold in the offering will be offered by the Company. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares sold in the public offering.

  • GlobeNewswire2 months ago

    Quotient Limited Announces Receipt of Consents to Modifications to the Company’s Senior Secured Notes

    Franz Walt, Quotient’s Chief Executive Officer noted, “the Proposed Amendments include a six-month extension of the final maturity of the Notes to April 2024 and a revision of the Notes' principal amortization (currently scheduled to commence semi-annually beginning April 2019) to commence April 2021, in order to better align the maturity and amortization schedule with our financial goals.  Mr. Walt added, “the revised amortization schedule will defer approximately $39.6 million of principal amortization currently scheduled to occur between April 2019 and April 2021. The Company issued an initial $84.0 million aggregate principal amount of the Notes in October 2016 and an additional $36.0 million aggregate principal amount of the Notes in June 2018.

  • GlobeNewswire2 months ago

    Quotient Limited Announces Initial MosaiQ™ SDS Verification and Validation Data

    Quotient Limited (QTNT), a commercial-stage diagnostics company (the Company), today reported positive Verification and Validation (V&V) concordance data for its initial MosaiQ™ Serological Disease Screening (SDS) Microarray. Results of the V&V head-to-head study for the initial MosaiQ™ SDS Microarray used for the detection of CMV and Syphilis achieved the required performance compared with predicate technologies.  The V&V data, which were derived using microarrays manufactured in Quotient’s ISO audited manufacturing facility and run on the recently CE marked MosaiQ™ instrument, represent the final step before moving to field trials for the initial SDS microarray currently planned for early in 2019. “The SDS microarray represents an important complement to the Company’s initial MosaiQ™ Immunohematology (IH) Microarray, which was submitted for CE mark approval in September 2018.

  • Quotient (QTNT) Q2 2019 Earnings Conference Call Transcript
    Motley Fool3 months ago

    Quotient (QTNT) Q2 2019 Earnings Conference Call Transcript

    QTNT earnings call for the period ending September 30, 2018.

  • Quotient (QTNT) Reports Q2 Loss, Tops Revenue Estimates
    Zacks3 months ago

    Quotient (QTNT) Reports Q2 Loss, Tops Revenue Estimates

    Quotient (QTNT) delivered earnings and revenue surprises of -47.22% and 7.71%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Quotient: Fiscal 2Q Earnings Snapshot

    On a per-share basis, the Eysins, Jersey-based company said it had a loss of 53 cents. The blood test developer posted revenue of $6.2 million in the period. Quotient shares have increased 31 percent since ...

  • Quotient (QTNT) Q2 Earnings Preview: What to Know Ahead of the Release
    Zacks4 months ago

    Quotient (QTNT) Q2 Earnings Preview: What to Know Ahead of the Release

    Quotient (QTNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.